Heron Therapeutics (HRTX) Competitors $1.26 -0.02 (-1.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.29 +0.03 (+2.38%) As of 09/12/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HRTX vs. KALV, AKBA, DAWN, TNGX, IMTX, NRIX, OCS, NAGE, VALN, and GYREShould you be buying Heron Therapeutics stock or one of its competitors? The main competitors of Heron Therapeutics include KalVista Pharmaceuticals (KALV), Akebia Therapeutics (AKBA), Day One Biopharmaceuticals (DAWN), Tango Therapeutics (TNGX), Immatics (IMTX), Nurix Therapeutics (NRIX), Oculis (OCS), Niagen Bioscience (NAGE), Valneva (VALN), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Heron Therapeutics vs. Its Competitors KalVista Pharmaceuticals Akebia Therapeutics Day One Biopharmaceuticals Tango Therapeutics Immatics Nurix Therapeutics Oculis Niagen Bioscience Valneva Gyre Therapeutics KalVista Pharmaceuticals (NASDAQ:KALV) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment. Do institutionals & insiders have more ownership in KALV or HRTX? 80.0% of Heron Therapeutics shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, KALV or HRTX? KalVista Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Does the media refer more to KALV or HRTX? In the previous week, KalVista Pharmaceuticals had 20 more articles in the media than Heron Therapeutics. MarketBeat recorded 25 mentions for KalVista Pharmaceuticals and 5 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.39 beat KalVista Pharmaceuticals' score of 0.60 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate KALV or HRTX? KalVista Pharmaceuticals currently has a consensus target price of $26.43, indicating a potential upside of 88.64%. Heron Therapeutics has a consensus target price of $4.50, indicating a potential upside of 257.14%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Heron Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has higher earnings & valuation, KALV or HRTX? Heron Therapeutics has higher revenue and earnings than KalVista Pharmaceuticals. Heron Therapeutics is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$183.44M-$3.94-3.56Heron Therapeutics$144.29M1.60-$13.58M-$0.02-63.00 Is KALV or HRTX more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Heron Therapeutics' return on equity of 0.00% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -162.69% -88.61% Heron Therapeutics -0.62%N/A -0.40% SummaryHeron Therapeutics beats KalVista Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Heron Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HRTX vs. The Competition Export to ExcelMetricHeron TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$234.64M$2.59B$5.85B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-63.0023.8575.3425.98Price / Sales1.60529.66514.54181.13Price / CashN/A171.1637.5660.44Price / Book-5.735.3712.156.29Net Income-$13.58M$32.95M$3.29B$271.07M7 Day Performance-3.82%1.28%0.74%3.87%1 Month Performance-10.00%6.09%4.82%4.88%1 Year Performance-32.62%-2.15%60.58%26.12% Heron Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HRTXHeron Therapeutics4.2296 of 5 stars$1.26-1.6%$4.50+257.1%-31.5%$234.64M$144.29M-63.00300Positive NewsKALVKalVista Pharmaceuticals4.0261 of 5 stars$15.96+0.9%$26.29+64.7%+33.9%$796.38MN/A-4.33100Trending NewsEarnings ReportAnalyst ForecastInsider TradeAKBAAkebia Therapeutics3.7178 of 5 stars$3.13+5.7%$6.75+115.7%+104.9%$784.83M$160.18M0.00430News CoveragePositive NewsAnalyst DowngradeDAWNDay One Biopharmaceuticals3.0993 of 5 stars$7.47-1.1%$25.29+238.5%-47.9%$773.36M$131.16M0.0060Positive NewsTNGXTango Therapeutics1.8269 of 5 stars$6.81-1.9%$10.50+54.2%-34.7%$772.15M$42.07M0.0090News CoverageInsider TradeIMTXImmatics2.9179 of 5 stars$5.81-7.2%$14.67+152.4%-53.3%$760.90M$168.65M0.00260Positive NewsNRIXNurix Therapeutics2.3792 of 5 stars$9.70-2.1%$29.07+199.7%-61.6%$757.61M$54.55M0.00300News CoveragePositive NewsOCSOculis3.1339 of 5 stars$17.25+0.2%$35.75+107.2%+45.6%$751.87M$780K0.002Analyst UpgradeShort Interest ↓NAGENiagen Bioscience2.2433 of 5 stars$9.45+0.4%$13.42+42.0%N/A$750.47M$99.60M72.39120Positive NewsAnalyst DowngradeVALNValneva2.8015 of 5 stars$8.52-1.5%$15.00+76.1%+28.1%$743.27M$183.52M0.00700Short Interest ↓Gap DownGYREGyre Therapeutics1.6848 of 5 stars$7.89+2.6%$18.00+128.1%-43.0%$740.65M$105.76M153.8040News CoveragePositive NewsAnalyst Revision Related Companies and Tools Related Companies KalVista Pharmaceuticals Competitors Akebia Therapeutics Competitors Day One Biopharmaceuticals Competitors Tango Therapeutics Competitors Immatics Competitors Nurix Therapeutics Competitors Oculis Competitors Niagen Bioscience Competitors Valneva Competitors Gyre Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HRTX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
